Dose Escalation For INtraprostatic LEsions

External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer. The current standard involves delivering radiotherapy uniformly throughout the prostate gland in daily fractions, five days per week, for approximately four weeks. In this study, radiotherapy will be delivered using an ultra-hypofractionated approach in three larger fractions on alternating days over one week Multiparametric magnetic resonance imaging will be used to guide focal dose escalation to parts of the gland harboring tumor, which could potentially reduce

Trial Details

NCT ID
NCT05851547
Phase
PHASE2
Sponsor
Ottawa Hospital Research Institute
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Prostate SBRT with Focal Boost
  • Triptorelin Injection
Locations (sample)
  • Ottawa, Ontario, Canada|45.41117,-75.69812

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma of the prostate
  • Unfavourable intermediate-risk or high-risk localized disease
  • Unfavourable intermediate-risk prostate cancer is defined as intermediate-risk prostate cancer \[that is, no high-risk features and one or more int…
  • High-risk localized prostate cancer is defined as at least one of the following: T3a-T3b; Gleason ≥ 8 (grade group 4 or grade group 5); PSA \> 20 μg/L

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →